Management of advanced stage Hodgkin lymphoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 3, 2006, Pages 241-247

  Advani, Ranjana ^a,b,c   Ai, Weiyun Z ^a,b   Horning, Sandra J ^a,b  

^a Stanford University Medical Center ^*

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

Hodgkin lymphoma; Prognostic factors; Risk adapted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; LOMUSTINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINDESINE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AVASCULAR NECROSIS; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESEARCH; CANCER RISK; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DOSE RESPONSE; DRUG FATALITY; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; INFERTILITY; INTERMETHOD COMPARISON; LEUKEMIA; LUNG FIBROSIS; LYMPH NODE IRRADIATION; LYMPHOMA; MULTIMODALITY CANCER THERAPY; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CANCER STAGING; RADIOTHERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY;

EID: 33645909114     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0023     Document Type: Review

References (40)

1. Longo D, Young R, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986;4:1295-1306.
2. DeVita VT Jr, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980;92:587-595.
3. Vose J, Bierman P, Anderson J, et al. CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicity. J Clin Oncol 1991;9:1421-1425.
4. Harding MJ, McNulty LJ, Paul J, et al. Mechlorethamine, vinblastine, procarbazine and prednisolone (MVPP) for advanced Hodgkin's disease. Eur J Cancer 1991;27:1002-1006.
5. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, et al. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease-long term results. Br J Cancer 1991;63:579-582.
6. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975;36:252-259.
7. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484.
8. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002;346:1417-1418.
9. Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996;14:1421-1430.
10. Glick JH, Young ML, Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998;16:19-26.
11. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607-614.
12. Viviani S, Santoro A, Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985;21:601-605.
13. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514.
14. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002;20:630-637.
15. Horning SJ, Hoppe R, Advani R, et al. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: mature data in early and advanced stage patients [abstract]. Blood 2004;104 Abstract 308.
16. Yahalom J, Edwards-Bennet S, Jacobs J, et al. Stanford V and radiotherapy for advanced and locally extensive Hodgkin's disease (HD): the Memorial Sloan-Kettering Cancer Center (MSKCC) experience [abstract]. Blood 2003 Abstract 1459.
17. Horning SJ, Williams J, Bartlett NL, et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492. J Clin Oncol 2000;18:972-980.
18. Aversa SM, Salvagno L, Soraru M, et al. Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. Acta Haematol 2004;112:141-147.
19. Johnson P, Hoskin P, Horwich A, et al. Stanford V (SV) regimen versus ABVD for the treatment of advanced Hodgkin lymphoma (HL): results of a UK NCRI/LTO randomised phase II trial [abstract]. Blood 2004;104 Abstract 311.
20. Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005;23:9198-9207.
21. Hasenclever D, Loeffler M, Diehl V. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1996;7[suppl 4]:95-98.
22. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395.
23. Connors JM: State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005;23:6400-6408.
24. Diehl V, Brillant C, Franklin J, et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9- and HD12- trials of the German Hodgkin Study Group (GHSG) [abstract]. Blood 2004;104 Abstract 307.
25. Sieber M, Bredenfeld H, Josting A, et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:1734-1739.
26. Markova J, Zidka M, Kozak T. Osteonecrosis as a complication of treating Hodgkin's lymphoma after BEACOPP chemotherapy. Ann Oncol 2005;16(Suppl 5). Abstract 269.
27. Federico M, Bellei M, Brice P, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to frontline therapy. J Clin Oncol 2003;21:2320-2325.
28. Proctor SJ, Mackie M, Dawson A, et al. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer 2002;38:795-806.
29. Young RC, Canellos GP, Chabner BA, et al. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 1978;42:1001-1007.
30. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 1998;16:818-829.
31. Ferme C, Sebban C, Hennequin C, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'etudes des lymphomes de l'Adulte H89 trial. Blood 2000;95:2246-2252.
32. Hancock SL, Hoppe RT, Horning SJ, et al. Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. Ann Intern Med 1988;109:183-189.
33. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003;348:2396-2406.
34. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22:62-68.
35. Friedberg JW, Fischman A, Neuberg D, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004;45:85-92.
36. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002;112:262-268.
37. Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004;90:620-625.
38. Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001;115:272-278.
39. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003;14:123-130.
40. Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98:2930-2934.